Holen Sie sich die Stockscreener-App
6.10
3.17%
-0.20
Vorhandelsmarkt:
6.10
Schlusskurs vom Vortag:
$6.30
Offen:
$6.435
24-Stunden-Volumen:
24,946
Relative Volume:
0.02
Marktkapitalisierung:
$7.11M
Einnahmen:
$1,000
Nettoeinkommen (Verlust:
$-11.39M
KGV:
-0.1986
EPS:
-30.7182
Netto-Cashflow:
$-7.26M
1W Leistung:
-10.29%
1M Leistung:
-55.25%
6M Leistung:
-81.37%
1J Leistung:
-89.79%
1-Tages-Spanne:
$5.84
$6.435
1-Wochen-Bereich:
$5.84
$7.00
52-Wochen-Spanne:
$3.1829
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
6.10 | 7.35M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
ERNA Q3 2023 Earnings: Pre-Revenue Biotech Reports Wider Loss as Stock DeclinesSubscription Growth Report - newsline.com
Ernexa Therapeutics (ERNA) Drops Over 6%: Key Support Levels in FocusFibonacci Fan - newsline.com
Number of shareholders of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics stock climbs on breakthrough preclinical data - MSN
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
Ernexa highlights ERNA-101's potential to improve ovarian cancer treatment with scalable, off-the-shelf cell therapy. - Pluang
Ernexa Therapeutics Highlights Innovative Cell Therapy Approaches for Ovarian Cancer in Virtual Investor KOL Connect Segment - Quiver Quantitative
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer - Yahoo Finance
ERNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ERNA Q3 2023 Earnings: Pre-Revenue Biotech Reports Wider Loss, Shares Tumble 12%EBITDA Analysis - newsline.com
Ernexa Therapeutics Warrants (ERNAW) Slide Over 20% as Key Support NearsPositive Gamma - The Legal Advocate
Ernexa Therapeutics Warrants Drop 21.76%: Warrants Plunge Below Key Support LevelMomentum ETF - The Legal Advocate
Ernexa Therapeutics (ERNA) Faces Sharp Sell-Off, Testing Key Support at $10.20Elliott Wave Count - newsline.com
Ernexa Therapeutics (ERNA) Surges 4.31%: Key Levels and Technical OutlookFloat Adjusted Cap - The Legal Advocate
Ernexa Therapeutics Inc. (ERNA) Q3 2023 Earnings: Negative EPS as Company Advances PipelinePre-Earnings Drift - The Legal Advocate
Number of shareholders of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Warrants (ERNAW) Slide Marginally to $0.15, Testing Key Support ZoneInverse ETF Flow - thelegaladvocate.com
Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing - Investing.com
Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing By Investing.com - Investing.com Australia
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development - The Globe and Mail
Ernexa Therapeutics (ERNA) Slides 2.5% as Weakness Persists Near Support LevelsTriple EMA - newsline.com
Ernexa stock is jumping today: What's going on? - MSN
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - bioinformant.com
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Net loss of $1.03 per share highlights ongoing clinical investment; stock declines 3.77%Annual Report - newsline.com
Ernexa Therapeutics Inc. (ERNA) Q3 2023 Earnings: Narrowing Losses Amidst Pipeline ProgressProfit Announcement - The Legal Advocate
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Deepening Losses and Clinical-Phase Uncertainty Weigh on SharesPro Level Trade Signals - Newser
Ernexa Therapeutics Q3 2023 Earnings: Losses Deepen as Stock Declines, No Revenue ReportedGuidance Revision Trend - Newser
Ernexa Therapeutics (ERNA) Slips 3.8% as Shares Test Key Support Near $11.39SMA Signal - The Legal Advocate
Clear Street exits ownership reporting for Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - sharewise.com
Ernexa Therapeutics Releases Virtual Investor KOL Connect - GlobeNewswire
ernexa therapeutics inc. Earnings dates - RTTNews
Ernexa Therapeutics (ERNA): Trustees report 66,751 shares, 5.6% stake - Stock Titan
ERNA stock almost doubled in value today – smashing rally leads to 7 trading halts - MSN
Ernexa Therapeutics Inc (ERNA) Stock Price, Quote, News & History - Benzinga
Ernexa Therapeutics (ERNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
ERNA | Ernexa Therapeutics Inc. Common Analyst Forecasts - Quiver Quantitative
Bleichroeder LP discloses 6.86% stake in Ernexa Therapeutics (ERNA) - Stock Titan
Clear Street LLC reports 12.8% stake in Ernexa (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) amendment: 118,342 shared holdings; 48,000 warrants noted - Stock Titan
Ernexa Stock Is Jumping Today: What's Going On? - Sahm
Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April - Sahm
Ernexa Therapeutics (ERNA) Stock Soars 78% Following Q1 Earnings and Pipeline Update - MEXC
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):